Search

everythinglearnresearchcommunity

for

Search:↓

Patients should consult urologists for evidence-based erectile dysfunction treatments.

The NAMS 2014 recommendations guide healthcare providers on treating health issues in midlife women, emphasizing individualized care and informed decision-making.

The meeting highlighted advances in sexual medicine and priapism management.

The conference reported improvements in muscle volume, skin cancer diagnosis, facial and vaginal rejuvenation, and hair growth using various laser treatments.

Transdermal testosterone can improve sexual desire in postmenopausal women but lacks long-term safety data and is not FDA-approved for this use.

Amenorrhea is relatively rare and initial testing should check FSH, TSH, and prolactin levels.

The document concludes that identifying the cause of amenorrhea is crucial for proper treatment.

The Endocrine Society advised against routine testosterone therapy for women, citing a need for more research on long-term safety and a clear definition of androgen deficiency.

Testosterone can help premenopausal and postmenopausal women with low sexual desire, but its long-term safety is unclear and it's not widely approved for this use.

The guideline provides healthcare professionals in South Africa with instructions for comprehensive, multidisciplinary gender-affirming care, including HIV prevention and treatment for transgender and gender diverse individuals.

The meeting highlighted promising genetic treatments for male fertility issues but noted concerns about certain cancer risks and ICSI safety.

Testosterone therapy may slightly increase sexual desire in women with HSDD but lacks broad recommendation due to safety concerns and limited approval.

Forensic medicine is crucial for justice and needs continuous innovation and technology integration.

The workshop successfully promoted better medicine use and international collaboration.

Antidepressants, 5α-reductase inhibitors, and isotretinoin can cause long-lasting sexual dysfunction.

Amenorrhea is when a woman doesn't have periods, with primary amenorrhea starting by age 15 or within five years of breast development, and secondary amenorrhea when periods stop for three months. It affects 3-4% of women not pregnant, breastfeeding, or in menopause, mainly due to polycystic ovary syndrome, hypothalamic amenorrhea, hyperprolactinemia, and ovarian failure.

Addressing underrepresentation in Parkinson's research is crucial for better treatments and understanding.

The conclusion is that standardizing testosterone measurement methods is essential for better diagnosis accuracy in women.

The document sets criteria for diagnosing long-term sexual dysfunctions caused by certain medications.

5α-reductase inhibitors increase the risk of sexual dysfunction, especially in men with enlarged prostate.

Young women with nonclassic congenital adrenal hyperplasia may experience worse sexual function and mild depression compared to healthy women.

The report recommends personalized treatment for women's sexual dysfunctions and more research on effective therapies.

Women with nonclassic congenital adrenal hyperplasia experience more sexual dysfunction and distress.

Hormones significantly affect women's sexual function, and more research is needed to improve treatments for sexual dysfunction with minimal side effects.

Some patients taking finasteride or dutasteride may have ongoing sexual problems and depression even after stopping the medication.

Androgen therapy might help some women with low libido, but it has risks and should be used carefully.

5-alpha reductase inhibitors slightly increase the risk of sexual and mood side effects, and breast growth in men.

Hormone treatments for transgender individuals generally improve mental health and physical transition, with some health risks that require medical supervision.

The document concludes that understanding hair and feather regeneration can help develop new regenerative medicine strategies.

Testosterone therapy can help improve sexual desire and function in postmenopausal women but may cause side effects and is not FDA-approved for this use.